The ibrutinib B-cell proliferation inhibition is potentiated in vitro by dexamethasone: Application to chronic lymphocytic leukemia.

@article{Manzoni2016TheIB,
  title={The ibrutinib B-cell proliferation inhibition is potentiated in vitro by dexamethasone: Application to chronic lymphocytic leukemia.},
  author={Delphine Manzoni and R{\'e}gine Catallo and Amel Chebel and L Baseggio and Anne-Sophie Michallet and Olivier Roualdes and J Magaud and Gilles A Salles and Martine Ffrench},
  journal={Leukemia research},
  year={2016},
  volume={47},
  pages={1-7}
}
New B-cell receptor-targeted therapies such as ibrutinib, a Bruton tyrosine kinase inhibitor, are now proposed for lymphoid pathologies. The putative benefits of its combination with glucocorticoids were evaluated here. We compared the effects of dexamethasone (DXM), ibrutinib and their in vitro combination on proliferation and metabolic stress markers in stimulated normal B-lymphocytes and in malignant lymphocytes from chronic lymphocytic leukemia (CLL) patients. In both cellular models, cell… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 4 times over the past 90 days. VIEW TWEETS
2 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-2 of 2 extracted citations

Similar Papers

Loading similar papers…